New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NVS;ARRY;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 18, 2014
07:29 EDTAZNPfizer less likely to pursue AstraZeneca after PD-L1 deal, says JPMorgan
Subscribe for More Information
07:18 EDTAZNWoodford confident in Astra, sees 50% chance of new Pfizer bid, Reuters reports
Investment manager Neil Woodford of Woodford Investment Management said he now has an even stronger belief in AstraZeneca (AZN), citing the company's strong product pipeline, and put the chances of a new takeover bid from Pfizer (PFE) at 50/50, reported Reuters, citing a statement from Woodford. Reference Link
06:39 EDTAZNAstraZeneca: 'Hard to comment' on whether Pfizer will come back, Reuters reports
Subscribe for More Information
November 17, 2014
16:52 EDTNVSNovartis' LCZ696 could change course of heart failure for patients, study shows
New data on Novartis' investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction shows it has the potential to change the course of the disease for patients. In August, Novartis presented topline results from the landmark PARADIGM-HF study showing LCZ696 was superior to ACE inhibitor enalapril on key endpoints, including significantly reducing the risk of CV death or heart failure hospitalization. The new analyses being presented for the first time at the American Heart Association Scientific Sessions 2014, with a paper being simultaneously published in Circulation, show that versus enalapril, LCZ696 significantly: reduced the risk of dying suddenly by 20% in HFrEF patients 45% of CV deaths and 36% of all cause deaths are sudden; reduced first and subsequent HFrEF hospitalizations by 21% and 23% respectively; reduced hospitalizations for a cardiovascular reason or for any reason both by 16%; reduced the need for more intense treatment at home by 16%; reduced emergency room visits because of rapid symptom worsening by 30%.
11:06 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:37 EDTAZNAstraZeneca to host investor day
Subscribe for More Information
07:16 EDTAZNMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
07:08 EDTAZNMedImmune presents positive Phase IIb data for mavrilimumab in RA
Subscribe for More Information
07:07 EDTAZNMedImmune presents new data in systemic lupus
Subscribe for More Information
06:43 EDTAZNAstraZeneca, Pfizer deal seen less likely after Merck transaction, Reuters says
Subscribe for More Information
November 16, 2014
15:07 EDTNVSNovartis says arthritis drug secukinumab met primary endpoint
Subscribe for More Information
13:36 EDTAZNAstraZeneca presents data from studies of lesinurad combined with allopurinol
Subscribe for More Information
November 14, 2014
14:53 EDTNVS, AZNCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
07:14 EDTNVS, AZNAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
13:32 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
07:16 EDTAZNBIT Congress to hold a conference
Subscribe for More Information
07:03 EDTAZNAstraZeneca initiates development program for Brilinta reversal agent
Subscribe for More Information
05:34 EDTAZNAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use